n/a
Article Publish Status: FREE
Abstract Title:

Metabolomics profiling reveals berberine-inhibited inflammatory response in human gingival fibroblasts by regulating the LPS-induced apoptosis signaling pathway.

Abstract Source:

Front Pharmacol. 2022 ;13:940224. Epub 2022 Aug 22. PMID: 36071855

Abstract Author(s):

Ying Zhang, Yanyang Guo, Wenjia Wei, Zhongxiao Zhang, Xiaodong Xu

Article Affiliation:

Ying Zhang

Abstract:

This article examines berberine's biological effects and molecular mechanisms with an inflammatory response model induced by lipopolysaccharide (LPS) in human gingival fibroblasts (HGFs) using metabolomics. The viability of HGFs was determined using the cell counting kit-8 (CCK8). ELISA was used to measure inflammatory cytokines, including interleukin-6 (IL-6), interleukin-1(IL-1), and tumor necrosis factor-(TNF-). An investigation of western blots was conducted to investigate the related proteins of apoptosis. Low concentrations of berberine (0.1, 0.5, and 1 μmol L) did not affect HGF growth, whereas high concentrations of berberine (5-25 μmol L) significantly activated cell proliferation. Berberine suppressed the elevated secretion of IL-6, IL-1β, and TNF-α induced by LPS in HGF. Western blot analysis showed that 10 μmol Lof berberine significantly inhibited LPS-induced apoptosis signaling pathway activation. Our results suggested that berberine could inhibit LPS-induced apoptosis and the production of proinflammatory mediators in HGFs cells. Berberine may be a potential therapeutic drug for the management of periodontitis.

Print Options


This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.